Skip Navigation

JNCI Journal of the National Cancer Institute 2005 97(12):868-869; doi:10.1093/jnci/dji169
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Cappuzzo, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cappuzzo, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 Oxford University Press

EDITORIAL

Erlotinib in Gliomas: Should Selection Be Based on EGFR and Akt Analyses?

Federico Cappuzzo

Affiliation of author: Division of Medical Oncology, Bellaria Hospital, via Altura 3, 40139-Bologna, Italy

Correspondence to: Federico Cappuzzo, MD, Division of Medical Oncology, Bellaria Hospital, via Altura 3, 40139-Bologna, Italy (e-mail: federico.cappuzzo@ausl.bo.it).

The first 10% of the full text of this article appears below.

Gliomas are the most common primary malignant neoplasm of the central nervous system in adults. Despite tangible progress, results remain disappointing, and median survival is 10–12 months (1). Several new drugs have been developed that interfere with specific cellular targets in cancer cells. Among them, small-molecule inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) were shown to be effective in the treatment of solid malignancies. Gefitinib (Iressa; AstraZeneca, Wilmington, DE) and erlotinib (Tarceva; Genentech, South San Francisco, CA) are both orally active, selective EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have produced impressive responses in a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?